Story · Medicine & Biotech

Lecanemab’s five-year report card lands in Boston

1 outlet · first reported by Longevity.Technology 2d ago

Coverage, in order

  1. 2d ago
    Longevity.Technology UK indie
    Lecanemab’s five-year report card lands in Boston

    Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing. Anybody on an anti-amyloid drug has probably wondered, at some point, whether they’ll ever get to stop. Eisai has a poster on exactly that. It’s numbered P001, it sits first…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.